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van den Borst B, Schols AM, de Theije C, Boots AW, Köhler
SE, Goossens GH, Gosker HR. Characterization of the inflammatory
and metabolic profile of adipose tissue in a mouse model of chronic
hypoxia. J Appl Physiol 114: 1619–1628, 2013. First published
March 28, 2013; doi:10.1152/japplphysiol.00460.2012.—In both obe-
sity and chronic obstructive pulmonary disease (COPD), altered
oxygen tension in adipose tissue (AT) has been suggested to evoke
AT dysfunction, subsequently contributing to metabolic complica-
tions. Studying the effects of chronic hypoxia on AT function will add
to our understanding of the complex pathophysiology of alterations in
AT inflammation, metabolism, and mass observed in both obesity and
COPD. This study investigated the inflammatory and metabolic pro-
file of AT after chronic hypoxia. Fifty-two-week-old C57Bl/6J mice
were exposed to chronic hypoxia (8% O2) or normoxia for 21 days,
after which AT and plasma were collected. Adipocyte size, AT gene
expression of inflammatory and metabolic genes, AT macrophage
density, and circulating adipokine concentrations were measured.
Food intake and body weight decreased upon initiation of hypoxia.
However, whereas food intake normalized after 10 days, lower body
weight persisted. Chronic hypoxia markedly reduced AT mass and
adipocyte size. AT macrophage density and expression of Emr1, Ccl2,
Lep, and Tnf were decreased, whereas Serpine1 and Adipoq expres-
sion levels were increased after chronic hypoxia. Concomitantly,
chronic hypoxia increased AT expression of regulators of oxidative
metabolism and markers of mitochondrial function and lipolysis.
Circulating IL-6 and PAI-1 concentrations were increased, and leptin
concentration was decreased after chronic hypoxia. Chronic hypoxia
is associated with decreased rather than increased AT inflammation,
and markedly decreased fat mass and adipocyte size. Furthermore, our
data indicate that chronic hypoxia is accompanied by significant
alterations in AT metabolic gene expression, pointing toward an
enhanced AT metabolic rate.
inflammation; COPD; oxidative metabolism; lipolysis
OBESITY AND CHRONIC OBSTRUCTIVE pulmonary disease (COPD)
are two major chronic conditions with high prevalence world-
wide (1, 27), and are increasingly occurring together (7, 42). In
obesity, both decreased and increased oxygen tension within
the adipose tissue (AT) have been suggested to contribute to
AT dysfunction and inflammation, which may subsequently
increase the risk for metabolic complications (9, 10, 23, 37).
Chronic hypoxemia in COPD, on the other hand, accelerates
loss of body and fat masses, in part by increasing the resting
metabolic rate (29, 33, 43). However, the effects of chronic
hypoxia on AT function remain incompletely understood.
Studying the effects of chronic hypoxia on AT function is
important because it may add to our understanding of the
complex pathophysiology of alterations in AT inflammation,
metabolism and mass observed in both obesity and COPD.
It is now well established that AT is an inflammatory and
metabolically active tissue (8). Hypoxia may induce AT dys-
function and inflammation via direct effects of low PaO2,
endoplasmic reticulum stress, oxidative stress, or other mech-
anisms (37). In obesity, the combination of hypertrophying
adipocytes and insufficient neovascularization may lead to
local hypoxic tissue areas and to hypoxia within large adi-
pocytes lying distant from capillaries (39). Indeed, in various
mouse models of obesity, local areas of hypoxia were demon-
strated in the AT (14, 31, 46). This was accompanied by
increased AT expression of hypoxia-responsive markers [e.g.,
glucose transporter (GLUT)-1 (31, 46), vascular endothelial
growth factor (VEGF) (46)], altered adipokine mRNA expres-
sion [e.g., increased leptin and plasminogen activator-inhibitor
(PAI)-1, decreased adiponectin (14)], increased mRNA expres-
sion of proinflammatory markers [e.g., tumor necrosis factor
(TNF)-, interleukin (IL)-6 (46)], and increased expression
and presence of F4/80 macrophages in the AT (31, 46). To
further substantiate the potential direct role of hypoxia on
adipocyte inflammation, many in vitro studies have been car-
ried out in which either murine (mostly 3T3-L1 cells) or human
adipocytes were exposed to hypoxia. Although these studies
used exposure to extreme, nonphysiological PaO2 (1% O2), the
majority of these studies have indeed reported gross hypoxia-
induced changes rendering adipocytes more proinflammatory
and altering their adipokine expression and secretion profiles
(14, 19, 45, 46, 48). Importantly, however, conflicting data
have also been reported (5, 9). It has been demonstrated that
chronic hypoxia substantially lowered the inflammatory re-
sponse in primary human adipocytes (5), and PaO2 in abdom-
inal subcutaneous AT was inversely associated with the ex-
pression of inflammatory markers in this fat depot (9).
The physiological cellular response to hypoxia includes
switching from oxidative to anaerobic metabolism. In vitro
studies have indeed shown increased expression of various
glucose transporters and other markers of glycolytic metabo-
lism and decreased expression of mitochondrial components
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and their major upstream regulator, peroxisome proliferator-
activated receptor (PPAR)- coactivator-1 (PGC-1) (19).
This shift would imply increased lactate production from
adipocytes, which is indeed observed in obesity (2) and after
hypoxia (24). Studies investigating the effect of altered oxygen
tension on lipolysis have yielded conflicting results. Both
extreme hypoxia (1% O2) (47) and hyperoxia (95% O2) (28)
enhanced lipolysis in 3T3-L1 adipocytes.
Chronic hypoxemia as a consequence of COPD may also
affect AT function. Recent studies have detected increased
mRNA expression of the proinflammatory markers CD40,
MAPK kinase 4, and c-Jun NH2-terminal kinase (36) and
increased expression of inhibitors of nuclear factor-B (35) in
abdominal subcutaneous AT biopsies from hypoxemic, under-
weight patients with COPD compared with normoxemic, over-
weight patients with COPD.
Although the data on the causal role of hypoxia on AT
dysfunction and inflammation appear robust, there are several
limitations that call for more research. Whereas AT hypoxia in
obesity is chronic (37), the in vitro studies cited above inves-
tigated hypoxia exposures of 2–24 h, which induced acute
effects. In addition, the level of hypoxia applied in these
studies was very extreme (1% O2), which does not reflect
physiological AT oxygen tension in obesity (3–11% O2) (10).
Third, given that immune cells within the AT play an important
role in (co-) driving AT dysfunction in obesity (20), an in vivo
model is the preferred model to allow for the interaction of
different cell types under hypoxic conditions. For these rea-
sons, we designed a model in which we exposed mice to 21
days of hypoxia (8% O2). This allowed us to investigate
whether the acute inflammatory and metabolic alterations ob-
served with acute, severe hypoxia also persist in a chronic
model with more physiologically relevant levels of hypoxia.
MATERIALS AND METHODS
Experimental procedure. Fifty-two-week-old male C57BL/6J mice
(Charles River Laboratories, Wilmington, MA) were exposed to
ambient air (normoxia, n  8) or chronic hypoxia (n  8) for 21 days.
We studied 52-wk-old mice, rather than the more commonly studied
young adult but not fully-grown 12-wk-old mice, to preclude increas-
ing body weight (and expanding fat mass) as a confounder. Mice at
age 52 wk remain weight-stable under control conditions. All mice
were housed in experimental chambers at 21°C with a 12-h dark/light
cycle. Mice received standard chow (V1534–000 ssniff R/M-H, ssniff
Spezialdiäten, Soest, Germany) and water ad libitum. Using the
proOX P110 (BioSpherix, Lacona, NY) system, O2 was replaced by
N2 in a stepwise manner to create normobaric oxygen levels of 12%
(day 1), 10% (day 2), and finally 8% (60.8 mmHg) on day 3. The latter
oxygen concentration was maintained for the remainder of the exper-
iment. Three to four mice were housed per cage. Daily food intake
was determined per cage, and mice were weighed daily. On day 21,
mice were anesthetized with isoflurane gas, the abdominal cavity was
opened, and aortic blood was collected into a heparin-coated 1-ml
syringe (Becton Dickinson, Breda, The Netherlands). Oxygen levels
and pH were measured immediately using the ABL 510 Blood Gas
Analyzer (Radiometer; Diamond Diagnostics, Holliston, MA) and
blood cell count was determined with the Coulter Ac T Diff hema-
tology Analyzer (Beckman Coulter, Woerden, The Netherlands).
Plasma was stored at 80°C until further analyses. Visceral adipose
tissue (VAT, epididymal) and subcutaneous adipose tissue (SCAT,
inguinal) pads were collected bilaterally and weighed. One specimen
of each was fixed in 4% formaldehyde, transferred to 70% ethanol,
and subsequently embedded in paraffin. The other was snap-frozen in
liquid nitrogen and stored at 80°C for later mRNA analyses. Lower
limb skeletal muscles (gastrocnemius, tibialis anterior, soleus, exten-
sor digitorum longus, and plantaris), liver, and spleen were dissected
and weighed. Two normoxic mice were excluded because of infec-
tion. The protocol was approved by the Committee for Animal Care
and Use of Maastricht University (project 2009-151).
Plasma adipokine assays. Plasma adipokine profiles were deter-
mined using the Luminex xMAP-technology (32). A Bio-Plex (Bio-
Rad, Veenendaal, The Netherlands) murine cytokine 6-plex panel was
used to quantify the concentrations of interleukin (IL)-1, IL-6,
keratinocyte-derived chemokine (KC), monocyte chemotactic protein
(MCP)-1, tumor necrosis factor (TNF)-, and chemokine (C-C motif)
ligand 5 (CCL5). Additionally, three independent single-plex panels
were executed to assess the concentrations of leptin, adiponectin, and
plasminogen activator-inhibitor (PAI)-1. All assays were performed
according to manufacturer instructions. Data analysis was performed
with a Luminex 100 IS 2.3 system (Luminex, Austin, TX) using the
Bio-Plex Manager 4.1.1 software (Bio-Rad). The lower limits of
detection (LLOD) of the cytokines and adipokines measured were
0.74 pg/ml for IL-6, 3.4 pg/ml for TNF-, 3.3 pg/ml for IL-1, 1.9
pg/ml for KC, 23.7 pg/ml for CCL5, 2.4 pg/ml for MCP-1, 0.7 ng/ml
for leptin, 6.5 pg/ml for PAI-1, and 6.5 g/ml for adiponectin.
Cytokine concentrations for the measurements below the LLOD were
computed using a maximum-likelihood estimation procedure (18, 44),
which was required for the IL-6 and KC data. It is well established
that simpler methods such as assuming the value of one-half of the
LLOD or omitting undetectable samples from analyses generate
biased estimates of the measures (13). Reproducibility statistics based
on computed data, on the other hand, are approximately unbiased
when less than half of the measurements are below the LLOD (18) as
was the case in our study.
Adipocyte size. VAT and SCAT paraffin sections (4 m) were
stained with hematoxylin-eosin, and nonoverlapping fields were pho-
tographed at 200	 magnification (Nikon Eclipse E800; Nikon Instru-
ments Europe, Amsterdam, The Netherlands). The areas of 400
unique adipocytes per fat pad were measured using computerized
software (Lucia GF, Version 4.81; Laboratory Imaging, Prague,
Czech Republic).
RT-qPCR analysis. Total RNA from VAT and SCAT was extracted
with the Rneasy Lipid Tissue Mini Kit (Qiagen, Venlo, The Nether-
lands) and reverse-transcribed into cDNA using the Transcriptor
cDNA synthesis kit (Roche Applied Sciences, Mannheim, Germany).
Complementary DNA was amplified using Sensimix SYBR & Fluo-
rescein Kit (GC Biotech, Alphen a/d Rijn, The Netherlands) on a
quantitative PCR machine (Bio-Rad). Table 1 presents an overview of
the target genes and primer sequences. Expression levels of target
genes were normalized for the expression of three stable housekeep-
ing genes (Ppia, Axin1, and Canx) using GeNorm software (Prim-
erdesign, Southampton, NY) (41).
Immunohistochemistry. Deparaffinized 4-m-thick sections of
VAT and SCAT were incubated with the antibody AIA31240 (San-
Bio, Uden, The Netherlands) directed against macrophages (26).
Macrophages were quantified on microscopic pictures at 200	 mag-
nification, and macrophage density was expressed as the number of
macrophages per 100 adipocytes. If crown-like structures (CLS;
aggregations of single or fused macrophages around a single adi-
pocyte) were encountered, their density was expressed as number of
CLS per 100 adipocytes.
Statistics. Differences between mice exposed to chronic hypoxia or
to normoxia were tested using Student’s t-tests or Mann-Whitney
U-tests as appropriate. Body weight changes during the experiment
were tested using repeated measures ANOVA. Differences in the
responses between VAT and SCAT were tested using linear regres-
sion analyses in which the interaction term of condition (normoxia vs.
hypoxia) and adipose depot (VAT vs. SCAT) were evaluated for
statistical significance. Correlations were tested using Pearson’s cor-
relation coefficient, r. Data are presented as means 
 SE. Analyses
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were performed using PASW Statistics 17.0 (SPSS, Chicago, IL). P 
0.05 was considered statistically significant.
RESULTS
Chronic hypoxia induces major hematological adaptations.
Table 2 summarizes the blood gas analyses and hematological
adaptations to chronic hypoxia. As expected, arterial PaO2 and
SaO2 were markedly lower in mice exposed to chronic hypoxia.
Furthermore, mice exposed to chronic hypoxia had lower pH
and lower HCO3 but normal PaCO2. Further differences in-
cluded increased hematocrit, erythrocyte count, hemoglobin
concentration, mean corpuscular volume, mean corpuscular
hemoglobin, and a decreased mean corpuscular hemoglobin
concentration in mice exposed to chronic hypoxia. In line with
acidosis, the significantly higher p50(a) (oxygen tension of
blood at half saturation) in mice exposed to chronic hypoxia
indicates a right-shift of the oxygen-hemoglobin dissociation
curve, which means a lower affinity of hemoglobin for oxygen,
suggesting improved delivery of oxygen to the tissues. Also,
chronic hypoxia led to an increased spleen weight by 263%
(P  0.001, data not shown).
Recovery of food intake but lower body weight during
chronic hypoxia. Directly after initiation of normobaric hyp-
oxia, a drop in food intake was observed, which reached its
nadir of 58% of starting food intake on day 3 (Fig. 1A). During
days 6–10, a complete recovery of food intake was observed,
and thereafter it remained stable throughout the remaining 11
days of the experiment. Starting body weights were not differ-
ent between the two groups (32.6 
 0.3 g vs. 33.1 
 0.6 g; P 
0.55). During days 0–6, body weight of mice exposed to
chronic hypoxia gradually decreased by 13% (Fig. 1B). Even
though their food intake reached normal values by day 10, their
body weights remained stably low throughout the rest of the
experiment.
Table 1. Gene names, proteins encoded by the genes, and primer sequences
Gene
Protein Encoded
by the Gene Forward Primer (5=-3=) Reverse Primer (5=-3=)
Hypoxia
Vascular endothelial growth factor A (Vegfa) VEGF-A CTGTACCTCCACCATGCCAAGT TCGCTGGTAGACATCCATGAACT
Solute carrier family 2 (facilitated glucose






EGF-like module containing, mucin-like,
hormone receptor-like sequence 1 (Emr1)
F4/80 GGATGTACAGATGGGGGATG CATAAGCTGGGCAAGTGGTA
Chemokine (C-C motif) ligand 2 (Ccl2) MCP-1 CCTGCTGTTCACAGTTGCC ATTGGGATCATCTTGCTGGT
Adipocytokines
Tumor necrosis factor (Tnf) TNF- CAGCGCTGAGGTCAATCTGCC TGCCCGGACTCCGCAA
Interleukin 6 (Il6) IL-6 ATGGATCCTACCAAACTGGAT TGAAGGACTCTGGCTTTGTCT
Interleukin 1 beta (Il1b) IL-1 GTAATGAAAGACGGCACACCCAC CCGTTTTTCCATCTTCTTCTTTGG
Interleukin 10 (Il10) IL-10 CCAAGCCTTATCGGAAATGA TTTTCACAGGGGAGAAATCG
Leptin (Lep) Leptin CAAGCAGTGCCTATCCAGA AAGCCCAGGAATGAAGTCCA
Adiponectin, C1Q and collagen domain
containing (Adipoq)
Adiponectin TGTTCCTCTTAATCCTGCCCA CCAACCTGCACAAGTTCCCTT
Serine (or cysteine) peptidase inhibitor,
clade E, member 1 (Serpine1)
PAI-1 GCCTCCTCATCCTGCCTAA GCCAGGGTTGCACTAAACAT
Oxidative metabolism
Peroxisome proliferative activated receptor,
gamma, coactivator 1 alpha (Ppargc1a)
PGC-1 CAACAATGAGCCTGCGAACA CTTCATCCACGGGGAGACTG
Peroxisome proliferative activated receptor,
gamma, coactivator 1 beta (Ppargc1b)
PGC-1 ACCCTGAGAAAGCGCAATGA CCCAGATGAGGGAAGGGACT
Transcription factor A, mitochondrial (Tfam) TFAM CCGGCAGAGACGGTTAAAAA TCATCCTTTGCCTCCTGGAA
Cytochrome c-1 (Cyc1) Cytochromec-1 GCATTCGGAGGGGTTTCCAG CCGCATGAACATCTCCCCA
Uncoupling protein 1 (mitochondrial, proton
carrier) (Ucp1)
UCP-1 GCGTACCAAGCTGTGCGATG GACGTTCCAGGACCCGAGTC
Adrenergic receptor, beta 3 (Adrb3) 3-AR AGGCAACCTGCTGGTAATCA TCCACAGTTCGCAACCAGTT
Cell death-inducing DNA fragmentation
factor, alpha subunit-like effector A
Cidea TGCTCTTCTGTATCGCCCAGT GCCGTGTTAAGGAATCTGCTG
Lipid metabolism
Peroxisome proliferator activated receptor
gamma (Pparg)
PPAR- CGGAAGCCCTTTGGTGACTT TGGGCTTCACGTTCAGCAAG
Sterol regulatory element-binding protein 1c
(Srebp1c)
SREBP-1c GATGTGCGAACTGGACACAG CATAGGGGGCGTCAAACAG








Peptidylprolyl isomerase A (Ppia) Cyclophilin A TTCCTCCTTTCACAGAATTATTCCA CCGCCAGTGCCATTATGG
Axin 1 (Axin1) Axin-1 AGTGGATCATTGAGGGAGAGA GCCCCAGGACGCTCGAT
Calnexin (Canx) Calnexin GCAGCGACCTATGATTGACAACC GCTCCAAACCAATAGCACTGAAAGG
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Circulating levels of cytokines and adipokines. Chronic
hypoxia increased plasma IL-6 and PAI-1 concentrations,
whereas leptin concentrations were decreased. Plasma concen-
trations of TNF-, IL-1, CCL5, MCP-1, KC, and adiponectin
remained unaltered after chronic hypoxia (Table 3).
Loss of AT and skeletal muscle mass and decreased adi-
pocyte size after chronic hypoxia. Whereas chronic hypoxia
decreased lower limb muscle weights by 10.5 
 2.5% (Table 4),
the loss of AT mass was much more pronounced (Fig. 2A). The
decrease in VAT was significantly greater than that of SCAT
(65% vs. 55%; P  0.001). In line with this finding,
adipocytes in VAT shrunk significantly more than those in
SCAT after chronic hypoxia (52% vs. 40%; P  0.001)
(Fig. 2B). A strong correlation was found between AT mass
and adipocyte size (VAT: r  0.935, P  0.001; SCAT: r 
0.808, P  0.001).
Chronic hypoxia induces upregulation of hypoxia-sensitive
genes in adipose tissue. Slc2a1, Vegfa, and Pfkfb3 are hypoxia-
inducible genes encoding glucose transporter-1 (GLUT-1),
vascular endothelial growth factor-a (VEGF-A), and the gly-
colysis-promoting enzyme 6-phosphofructo-2-kinase/fructose-
2,6-biphosphatase 3 (PFKFB3), respectively (22, 38). Chronic
hypoxia increased expression of Slc2a1 in SCAT and Vegfa
and Pfkf3b in both SCAT and VAT (Fig. 3), suggesting that
despite the hematological adaptations described above, oxygen
delivery to AT was insufficient, resulting in a reduced AT PaO2.
The degree of upregulation of these genes was similar in VAT
and SCAT.
Chronic hypoxia attenuates the inflammatory profile in VAT
and SCAT. AT macrophages are considered to be pivotal
players in adipose tissue inflammation (20). In both VAT
and SCAT of mice exposed to chronic hypoxia, we found
significantly lower gene expression of key markers related
to macrophage presence (Emr1) and macrophage recruit-
ment (Ccl2) (Fig. 4A). This was confirmed by lower mac-
rophage density in both VAT and SCAT (Fig. 4, B and C).
The decreases in macrophage markers and density were not
different between VAT and SCAT. CLS counts were too
low to draw a firm conclusion, but tended to be lower in
mice exposed to chronic hypoxia, particularly in VAT (data
not shown).
In addition, gene expression of Tnf, Il10, and Lep was lower
in VAT of mice exposed to chronic hypoxia, whereas expres-
sion of Adipoq and Serpine2 was increased (Fig. 5A). SCAT of
mice exposed to chronic hypoxia was further characterized by
lower expression of Il10 and Lep, and an increased Serpine2
expression (Fig. 4B). The decrease in Lep and the increase in






Hypoxia (n  6) P
Arterial blood gas analysis
pH 7.28 
 0.01 7.11 
 0.02 0.001
PaO2, mmHg 129.8 
 3.7 34.3 
 1.6 0.001
PaCO2, mmHg 35.1 
 2.7 35.0 
 1.4 0.975
HCO3
, mmol/liter 15.9 
 1.1 10.7 
 0.7 0.002
SaO2, % 100 
 0.4 24 
 2.4 0.001
Base excess, mEq/liter 9.7 
 0.9 21.2 
 1.4 0.001
Hematological adaptations
Hematocrit, % 45 
 1 76 
 1 0.001
Hemoglobin, mmol/liter 9.0 
 0.3 14.4 
 0.1 0.001
Erythrocytes, x106 10.0 
 0.2 13.5 
 0.2 0.001
MCV, fL 45.6 
 0.3 56.1 
 0.8 0.001
MCH, pg 0.91 
 0.01 1.07 
 0.02 0.001
MCHC, g/dl 19.8 
 0.2 19.0 
 0.3 0.026
p50(a) 29.7 
 0.4 51.6 
 0.9 0.001
Values are means 
 SE. MCV, mean corpuscular volume; MCH, mean
corpuscular hemoglobin, MCHC, mean corpuscular hemoglobin concentra-
tion.
P<.001
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Fig. 1. Hypoxia reduces food intake and body weight, but only food intake recovers. A: food intake as percentage of starting food intake. Three to four mice
were housed per cage. Data represent the mean food intake per mouse, relative to day 0. B: body weight as percentage of starting body weight.





(n  8) P
IL-6, pg/ml 0.46 (0.37, 0.87) 1.12 (0.72, 2.45) 0.044
TNF-, pg/ml 25.1 (23.5, 61.5) 33.3 (25.1, 69.1) 0.467
IL-1, pg/ml 27.1 (15.9, 36.4) 25.7 (15.9, 35.7) 0.896
KC, pg/ml 10.6 (4.1, 13.6) 12.1 (5.1, 18.1) 0.651
CCL5, pg/ml 139 (107, 188) 167 (140, 209) 0.332
MCP-1, pg/ml 31.7 (25.3, 38.8) 33.5 (26.2, 40.5) 0.696
Leptin, ng/ml 8.9 (6.1, 11.9) 4.6 (4.2, 5.1) 0.002
Adiponectin, g/ml 31.8 (27.3, 38.7) 32.1 (27.4, 43.0) 0.897
PAI-1, ng/ml 1.3 (1.1, 1.7) 2.4 (2.3, 3.0) 0.002
Values are medians and 95% confidence intervals. IL, interleukin, TNF-,
tumor necrosis factor-; KC, keratinocyte-derived chemokine; CCL5, chemo-
kine (C-C motif) ligand 5; MCP-1, monocyte chemotactic protein-1; PAI-1,
plasminogen activator-inhibitor-1.
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Adipoq expression were more pronounced in VAT than in
SCAT. Additionally, the decrease in Il10 expression was
greater in SCAT compared with that of VAT. The lower
expression of Il1b in mice exposed to chronic hypoxia did not
reach statistical significance, and no changes were observed in
Il6 expression.
Chronic hypoxia increases expression of genes involved in
oxidative and lipid metabolism in AT. We found significantly
higher expression of regulators and markers of oxidative me-
tabolism in the AT of mice exposed to chronic hypoxia (Fig.
5B). VAT of mice exposed to chronic hypoxia was character-
ized by increased Ppargc1a, Ppargc1b, Tfam, Adrb3, Cyc1,
Ucp1, and Cidea expression. Congruently, SCAT of mice
exposed to chronic hypoxia was characterized by increased
Ppargc1b, Adrb3, Cyc1, and Ucp1 expression. The expression
of the adipogenesis marker Pparg and of the lipogenesis
marker Srebp1c were unchanged, whereas expression of the
lipolysis markers Lipe and Pnpla2 was increased in both VAT
and SCAT of mice exposed to chronic hypoxia (Fig. 5C).
Furthermore, the expression of Pck1, encoding phosphoenol-
pyruvate carboxykinase (PEPCK), was significantly increased
in both VAT and SCAT of these mice (Fig. 5C). None of the
chronic hypoxia-induced changes in metabolic gene expression
were different between VAT and SCAT.
The alterations in metabolic gene expression after chronic
hypoxia, in particular the markedly increased Ucp1 expression,
suggest browning of these white adipose tissue pads. Interest-
ingly, we found that the adipose tissue pads were indeed
characterized by a brown appearance (Fig. 6).





Hypoxia (n  8) P
Peripheral skeletal muscle, mg
Gastrocnemius muscle 317 
 2.2 276 
 4.0 0.001
Tibialis muscle 117 
 1.3 106 
 1.6 0.001
Plantaris muscle 41.2 
 0.8 36.0 
 0.8 0.001
Extensor digitorum longus muscle 27.5 
 0.4 24.6 
 0.4 0.001
Soleus muscle 21.7 
 0.4 20.2 
 0.6 0.096
















































Fig. 2. Chronic hypoxia reduces adipose tissue weight and adipocyte size in visceral (VAT) and subcutaneous adipose tissue (SCAT). Mice were killed after 21
days of normoxic (n  6) or hypoxic (n  8) conditions and VAT and SCAT were isolated. A: bilateral VAT and SCAT weights were significantly reduced
after chronic hypoxia. The reduction was more pronounced in VAT. B: decreased adipocyte size after chronic hypoxia. The effect was more pronounced in VAT.

























Fig. 3. Expression of hypoxia-inducible genes is increased in adipose tissue
after chronic hypoxia exposure. Mice were killed after 21 days of normoxic
(n  6) or hypoxic (n  8) conditions, and VAT and SCAT were collected.
Messenger RNA expression was corrected for a stable GeNorm factor and
presented relative to the levels in VAT of normoxic mice. Expression levels
of Vegfa (encoding vascular endothelial growth factor-A, VEGF-A), Pfkfb3
(encoding 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3, PFKFB3), and
Slc2a1 (encoding glucose transporter 1, GLUT-1) were measured. *P  0.05.
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DISCUSSION
In mice exposed to chronic hypoxia, we found consistent
evidence of decreased AT inflammation and alterations in
metabolic AT gene expression, suggesting increased oxida-
tive metabolism and enhanced lipolysis. In view of the
proinflammatory and oxidative-to-glycolytic shifts that have
been documented after exposing adipocytes to acute and
severe hypoxia in vitro, and of studies in obese mice
suggesting a link between AT hypoxia and local inflamma-
tion, our findings may be unexpected. However, the present
findings are in line with those in previous reports showing
that abdominal subcutaneous AT PaO2 was significantly
increased rather than decreased in obese insulin–resistant
individuals, and was positively associated with AT gene
expression of several proinflammatory markers (9). In that
study, the lower AT PaO2 in obesity seemed to be due to
decreased in vivo abdominal subcutaneous AT oxygen con-
sumption, suggesting a lower metabolic rate of AT in obese
subjects. Furthermore, abdominal subcutaneous AT PaO2



























































Fig. 4. Reduced adipose tissue macrophage infiltration after chronic hypoxia. Mice were killed after 21 days of normoxic (n  6) or hypoxic (n  8) conditions,
and VAT and SCAT were collected. A: decreased mRNA levels of the macrophage markers Emr1 (encoding F4/80) and Ccl2 (encoding monocyte chemotactic
protein-1, MCP-1) were observed in VAT and SCAT after chronic hypoxia. Messenger RNA expression was corrected for a stable GeNorm factor and presented
relative to the levels in VAT of normoxic mice. B: adipose tissue macrophage density was assessed by quantification of immunohistochemically stained
macrophages. A significant decrease was observed in adipose tissue (AT) of mice exposed to chronic hypoxia. C: representative pictures illustrate decreased AT
macrophage density and adipocyte size after exposure to chronic hypoxia (at 200	 magnification). Arrows point toward AT macrophages.
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and VEGFA (9). The present data suggest that these asso-
ciations may also hold in a model of chronic hypoxia.
Congruently, it has recently been reported that primary
human SCAT-derived adipocytes from overweight individ-
uals displayed reduced expression of nuclear factor-B
related genes (including CCL2), and showed a blunted
response to TNF- stimulation in terms of CCL2 expression
and protein secretion when exposed to hypoxia (5). Our data
underline the complexity of the effects of hypoxia on AT
function and suggest important differences between acute
and chronic effects. To the best of our knowledge, no
previous study has investigated AT function after exposure
to chronic hypoxia, precluding direct comparisons.
The gross phenotypical changes in mice exposed to
chronic hypoxia should not be disregarded when interpret-
ing AT inflammatory and metabolic alterations. Chronic
hypoxia markedly reduced fat mass and, congruently, de-
creased adipocyte size. This may have contributed to de-
creased AT inflammation. Indeed, adipocyte size has been
recognized as an important determinant of adipokine expres-
sion and secretion, with large adipocytes being more proin-
flammatory than small adipocytes (34). During the course of
hypertrophy, adipocytes produce CCL2, and fatty acids
released from hypertrophied adipocytes can bind Toll-like
receptor 4 complex, thereby activating an inflammatory
response in AT macrophages (15). Conversely, our data on
smaller adipocytes, decreased AT Ccl2 and Emr1 expres-
sion, and decreased AT macrophage density suggest that
these mechanisms of AT macrophage infiltration and acti-
vation are significantly attenuated after chronic hypoxia.









































































































Fig. 5. Significant alterations in adipose tis-
sue gene expression of cytokines and adipo-
kines and of key markers of oxidative and
lipid metabolism after chronic hypoxia. Mice
were killed after 21 days of normoxic (n  6)
or hypoxic (n  8) conditions, and VAT and
SCAT were collected. A: mRNA levels of
specific cytokines and adipokines in AT of
mice exposed to normoxia or chronic hypoxia.
B: increased mRNA levels of regulators and
markers of oxidative metabolism in AT of mice
exposed to chronic hypoxia. C: mRNA levels of
lipolysis-related markers in adipose tissue of
mice exposed to normoxia or chronic hypoxia.
Messenger RNA expression was corrected for a
stable GeNorm factor and presented relative to
the levels in VAT of normoxic mice. *P  0.05
for within-fat pad comparisons, #P  0.05 for
between-fat pad comparisons.
1625Hypoxia, Adipose Tissue Inflammation, and Metabolism • van den Borst B et al.
J Appl Physiol • doi:10.1152/japplphysiol.00460.2012 • www.jappl.org
Downloaded from journals.physiology.org/journal/jappl at Universiteit Maastricht (137.120.151.052) on May 8, 2021.
Low-grade systemic inflammation associated with ele-
vated IL-6 has been suggested to play a pivotal role in both
obesity and COPD, and AT has been considered an impor-
tant contributor in both diseases (3, 40). It has previously
been shown that sustained hypoxia results in increased
levels of circulating IL-6 (16, 30), which is confirmed by the
current data. Also, chronic hypoxia almost doubled the
concentrations of circulating PAI-1, which is a main inhib-
itor of fibrinolysis. This is in line with a previous study (25),
and with the well-known association between systemic in-
flammation and a prothrombotic state (4). The changes in
circulating PAI-1 and leptin concentrations after chronic
hypoxia were paralleled by changes in AT gene expression
of these adipokines. However, AT IL-6 gene expression was
unchanged and other proinflammatory markers were even
decreased. This suggests that chronic hypoxia-enhanced
circulating IL-6 levels and likely chronic hypoxia-induced
low-grade systemic inflammation in general, are not ac-
counted for by AT.
In our model, exposure to hypoxia initially induced sig-
nificant weight loss and decreased food intake, but after 10
days, food intake completely normalized, whereas body
weight remained stably low. These data suggest that a new
homeostatic equilibrium was established, which is charac-
terized by a hypermetabolic state. Interestingly, this was
accompanied by major changes in AT metabolic gene expres-
sion that collectively suggest increased mitochondrial biogenesis,
mitochondrial function, and lipolysis after chronic hypoxia. Given
this specific pattern of metabolic gene expression, it is tempting to
speculate that AT remodeling occurred via chronic stimu-
lation of adipocytic 3-adrenergic receptors (3-AR). In-
deed, nor-adrenergic remodeling of white AT is character-
ized by an elevation of the metabolic rate, an expansion of
mitochondrial mass, and upregulation of fatty acid oxidation
genes, and has even been shown to induce uncoupling
protein-1 (UCP-1), which is typically a brown AT marker
(17, 21). Hormone-sensitive lipase-mediated lipolysis has,
notably, been recognized as an important component of AT
remodeling following 3-AR activation (21). Additionally,
PEPCK (encoded by Pck1) is a key mediator of glyceroneo-
genesis, which involves reesterification of fatty acids to
triacylglycerol serving adipocytic retention rather than se-
cretion of fatty acids (12). In brown AT, it has been
suggested that glyceroneogenesis regulates the delivery of
fatty acids to the mitochondria, allowing for UCP-1 activa-
tion (12). Moreover, Pck1 transcription is induced by nor-
adrenergic stimulation in brown AT (11) and in white AT
proinflammatory cytokines inhibit Pck1 expression (6). 3-
adrenergic remodeling is induced by chronic cold exposure
(17); therefore, a limitation of the present study is that we
did not assess body temperature nor apply a thermoneutral
environment. For these reasons, we cannot fully exclude
that part of our findings can be explained by relative cold
exposure in mice exposed to chronic hypoxia. Because
metabolic remodeling of white AT is receiving a great deal
of attention in the combat against obesity, our finding of this
phenomenon coinciding with decreased AT inflammation
may be relevant to the obesity field. The lower fat mass and
the markedly reduced adipocyte size point toward increased
lipolysis after chronic hypoxia, which is further supported
by the increased gene expression of the key lipolytic en-
zymes HSL and ATGL, and the unchanged gene expression
of the adipogenic/lipogenic markers PPAR- and SREBP-
1c. A limitation of this study, however, is that we did not
assess systemic markers of lipolysis due to limited avail-
ability of material.
In conclusion, chronic hypoxia is associated with decreased
rather than increased AT inflammation, and markedly de-
creased fat mass and adipocyte size. Furthermore, our data
indicate that chronic hypoxia is accompanied by alterations in
AT metabolic gene expression, pointing toward an enhanced
AT metabolic rate.
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